SM
XFOR icon

Scoggin Management’s X4 Pharmaceuticals XFOR Stock Holding History

Scoggin Management’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-16,160
Closed -$567K – 60
2023
Q1 		$567K Buy
+16,160
New +$474K 0.33% 39

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TLP
Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Scoggin Management's XFOR Position: Q2 2023 in Review

Scoggin Management sold out of X4 Pharmaceuticals (XFOR) in Q2 2023, closing a stake of 16,160 shares — an estimated $567K sold.

Scoggin Management first reported a position in XFOR in Q1 2023 and held it in 1 quarter. The position peaked at $567K in Q1 2023. 95 funds tracked by Wall St. Rank hold XFOR as of Q2 2023.

  • Scoggin Management reported no remaining X4 Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Scoggin Management sold 16,160 X4 Pharmaceuticals shares in Q2 2023, an estimated $567K.
  • Scoggin Management first reported a position in X4 Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Scoggin Management's X4 Pharmaceuticals position peaked at $567K in Q1 2023.
  • 95 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2023.

Based on Scoggin Management's 13F filing for Q2 2023, filed 14 Aug 2023.